• NeuroThera Labs began pursuing FDA Orphan Drug Designation for SCI-110 in adult Tourette syndrome.
• RK Strategies was retained to support the US regulatory and policy push aimed at improving market access.
• SCI-110 is in a Phase IIb program following Phase IIa results showing 21% average tic reduction on the YGTSS Total Tic Score.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurothera Labs Inc. published the original content used to generate this news brief via TheNewswire (Ref. ID: 202609020810TNWSWRCACNPR_____1kogFZ9rb) on September 02, 2026, and is solely responsible for the information contained therein.